inclisiran
Novartis Expands Leqvio’s Potential After Successful Phase III Study Demonstrates Significant Cholesterol Reduction
Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease
Actionable Insights Powered by AI
Novartis, Leqvio, inclisiran, cholesterol reduction, Phase III study, ASCVD, LDL-C, cardiovascular disease